Expression of B-cell activating factor in pediatric patients with immune thrombocytopenia: a single institutional series and review of literature

J Immunoassay Immunochem. 2023 Jan 2;44(1):41-55. doi: 10.1080/15321819.2022.2114363. Epub 2022 Sep 1.

Abstract

B-cell-activating factor (BAFF) is a crucial cytokine supporting survival and differentiation of B cells. Dysregulation of BAFF is involved in the pathogenesis of B-cell related autoimmune diseases including immune thrombocytopenia (ITP). The aim of this study was to evaluate the significance of BAFF expression in pediatric ITP patients. Eighty pediatric patients with ITP are subdivided in three groups. Group I included (32 patients) diagnosed with acute ITP less than 3 months, group II (48 patients) diagnosed with persistent ITP (from 3 to 12 months) and chronic ITP (more than 12 months) and group III 20 healthy controls. Complete blood picture, autoimmune profile, antiplatelet antibodies, coagulation profile, bone marrow examination, and RT-PCR were performed to detect the expression for BAF for all participants in this study. BAFF expression levels significantly increased in cases rather than in controls. BAFF Expression Value significantly increased in groups I & II (3.10 ± 1.99&3.29 ± 2.58) compared to controls (0.83 ± 0.45) as p < .001 for both. On the other hand, groups I & II were comparable in BAFF Expression Value (p = .470). BAFF expression increased in ITP patients, implying a function in the disease's pathogenesis.

Keywords: B-cell activating factor; ITP; RT- PCR.

Publication types

  • Review

MeSH terms

  • B-Cell Activating Factor
  • B-Lymphocytes
  • Child
  • Cytokines
  • Humans
  • Interleukin-4
  • Purpura, Thrombocytopenic, Idiopathic* / diagnosis

Substances

  • B-Cell Activating Factor
  • Cytokines
  • Interleukin-4